Regula Helps Austrian Municipalities Facilitate ID Verification and Processing
10.9.2024 08:00:00 CEST | Business Wire | Press release
Municipal registration offices across Austria have integrated advanced document readers Regula 7024M to automate and secure identity verification processes. This initiative is part of the “Sicheres Meldeamt” (secure registration office) project, launched by the Federal Ministry of Internal Affairs of Austria.
In Austria, the municipal registration office (Meldeamt) plays a crucial role in the administrative process for both citizens and residents. It's where individuals are required to register their place of residence, which is an essential part of living in Austria. However, its role extends beyond mere registration; it facilitates a smooth transition for individuals moving within or to Austria, granting them access to public services and contributing to orderly municipal management.
The need for modernization
Traditionally, the verification of identity documents in Austrian registration offices has been based predominantly on manual work, which requires a certain level of expertise, is time-consuming and prone to errors. Recognizing the need for more efficient and hurdle-free operations, theMinistry of Internal Affairs has launched the “Sicheres Meldeamt” initiative and has offered registration offices a new approach to automate identity document reading and verification.
The solution
To realize the “Sicheres Meldeamt” project across the whole country, cooperation with IT service providers to Austrian registration offices was initiated. Among these providers are Kufgem, Gemdat OÖ, PSC, Comm-Unity EDV, Gemdat NÖ, and others. They have offered to equip registration offices with compact desktop document readers Regula 7024M.
Regula’s devices were chosen because they feature advanced OCR technology tailored for identity documents, MRZ and barcode reading modules, and multiple light sources. It helps Regula 7024M accurately identify various data types, including engraved and embossed text. Additionally, the device comes equipped with an RFID chip reading module to enable the verification of biometric documents. By performing extensive data cross-checks, Regula 7024M helps identify any possible inconsistencies in personal information that may indicate fraud.
First results and future prospects
The pilot projects in cities like Linz, Telfs, and Sankt Pölten have shown significant improvements in the registration processes. With Regula 7024M, documents are processed instantaneously, significantly reducing the manual workload and virtually eliminating human error.
Christoph Heichinger, Ministerial Councillor from the Central Office of the Federal Ministry of Internal Affairs of Austria and one of the project managers of the “Sicheres Meldeamt” project, stated, "The digital enhancement of the registration process allows registration offices to create effective protection mechanisms against the unauthorized use of registration confirmations. This is achieved by using high-quality passport and document readers for verifying documents."
Now, the “Sicheres Meldeamt” project is going to be extended to other registration offices in Austria.
“We are immensely proud to see our document readers streamlining and securing ID processing in Austrian registration offices. Regula 7024M is a powerful tool capable of transforming the daily operations of border controls and immigration services. This initiative sets a new nationwide benchmark for identity verification and we look forward to continuing our support for the ‘Sicheres Meldeamt’ project as it expands across the country,” said Maris Kaminskis, Executive Director at Regula Europe.
To learn more about Regula’s involvement in the “Sicheres Meldeamt” project, please read the success story.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909830261/en/
Contacts
Kristina – ks@regulaforensics.com
Kristina – ks@regulaforensics.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom